Last updated: May 17, 2026
SYNERCID (quinupristin/dalfopristin) remains a niche hospital antibiotic with limited expansion prospects because it is not positioned for broad guideline replacement of modern alternatives (MRSA, linezolid/daptomycin, ceftaroline, newer agents). Public clinical activity is sparse relative to currently competitive antibacterial franchises, and commercial trajectory is constrained by formulary preference, spectrum-driven switching, and aging patient populations typical for chronic-care MRSA patterns. Market exposure is therefore best modeled as a declining base with periodic utilization spikes (seasonal skin/soft tissue and complicated SSTI) rather than a growth curve.
What is Synercid (quinupristin/dalfopristin) and what is its current FDA status?
SYNERCID is a streptogramin combination antibiotic (quinupristin + dalfopristin) used in the US for specific serious bacterial infections, with prescribing concentrated in inpatient and hospital specialty settings where susceptibility and stewardship protocols align.
What is Synercid’s labeling indication set in the US?
SYNERCID is marketed in the US under FDA approval for serious infections caused by susceptible Gram-positive bacteria. The actionable commercial point is that the product remains used where susceptibility testing and institutional policies support streptogramin use, rather than serving as a default therapy class for MRSA or VRE.
Is Synercid on the Orange Book?
SYNERCID is an FDA-approved product; exclusivity and patent status in the US are governed by the Orange Book listing for the listed NDA (and any associated patents). Market-wide projections depend on whether remaining patents are enforceable against generics and whether any ANDA approvals exist. No Orange Book listing or patent barrier details are provided in the available input set, so exclusivity-to-launch timing cannot be stated accurately here.
What is the regulatory pattern that affects Synercid competition?
SYNERCID faces competitive substitution from:
- MRSA agents: linezolid, daptomycin, telavancin (where used), ceftaroline
- VRE options: linezolid (selected uses), daptomycin (off-label/label dependent), newer pipeline drugs that capture formulary mindshare
What clinical trials are currently active or recently completed for Synercid?
No specific ongoing or recently completed Synercid interventional studies with dates, NCT numbers, endpoints, and recruiting status are included in the provided input. Without trial identifiers and verified milestones, a clinical-trials update cannot be constructed without risking factual errors.
Which endpoints would matter commercially if new Synercid trials start?
- Clinical cure in complicated SSTI and bacteremia due to susceptible Gram-positives
- Microbiologic eradication in MRSA/VRE subgroups
- Safety/tolerability in inpatient populations (especially infusion reactions and hepatobiliary tolerability)
- Noninferiority vs. standard-of-care comparator regimens
What trial signals would change market share?
- Demonstrated superiority or durable noninferiority in MRSA bloodstream infection compared with linezolid/daptomycin
- Stewardship-driven evidence supporting empiric or early targeted use (label expansion)
- Shorter infusion regimens or simplified administration protocols that reduce nursing burden
How big is Synercid’s market, and how should it be sized for forecasting?
A precise market model requires sales/usage history (US + any ex-US markets), prescribing data by setting (acute vs long-term care), and formulary penetration. The provided input does not include:
- historical revenue by year
- usage volume (DUR units) or patient counts
- geography breakdown
- channel mix (hospital outpatient vs inpatient)
- competitor utilization shifts
Because none of those inputs are available in the prompt, the only defensible forecast is a directional framework, not numeric projections.
Market structure that drives Synercid utilization
SYNERCID use is typically concentrated in:
- tertiary hospitals with active infectious disease programs
- centers with antibiogram patterns supporting streptogramin susceptibility
- salvage therapy settings after failure/intolerance of first-line options
What competitive forces most influence Synercid volume
- Linezolid and daptomycin guideline anchoring for MRSA
- Emerging preference for less complex administration regimens
- Antimicrobial stewardship tightening around “reserve” agents
- Drug safety and infusion monitoring burden relative to competitors
When does Synercid lose exclusivity, and what generic entry risks exist?
Exclusivity timelines and generic entry risks require Orange Book patent and exclusivity tables (listed patents, expiration dates, and any pediatric exclusivity). The provided input does not contain the Orange Book data required to identify:
- specific patent expiration dates (composition, formulation, method-of-use, or manufacturing)
- exclusivity end dates
- whether any ANDA has been filed or approved
- whether Paragraph IV challenges occurred
How would Paragraph IV filings change the forecast?
A credible forecast would incorporate:
- expected “first generic” entry date
- probable settlement timing
- anticipated branded-to-generic substitution pace in hospital formularies
- price erosion magnitude for hospital-only specialty antibiotics
Those inputs are not present.
What patent estate protects Synercid, and how strong is it?
Patent estate strength depends on:
- number of listed Orange Book patents by type
- claim breadth (composition vs process vs method-of-use)
- litigation history and Federal Circuit posture
- country-by-country filings (US, EP, etc.)
No patent list or litigation record is provided in the prompt; therefore, a patent strength assessment cannot be completed accurately.
What formulations are protected for Synercid, and what manufacturing/IP barriers exist?
Formulation and manufacturing barriers require:
- patent claims addressing formulation composition, stability, reconstitution, infusion preparation, or particle characteristics
- process patents covering production steps, sterilization, or stability constraints
- know-how or equipment constraints relevant to scale-up
None of those details are included. A claims-level analysis cannot be produced without risking incorrect statements.
What patent litigation affects Synercid and could affect supply?
Litigation impact requires:
- case captions, court, docket numbers
- asserted patents and outcomes (dismissal, summary judgment, settlement dates)
- settlement terms that may include launch dates or “design-around” approvals
No litigation details are included, so this section cannot be populated.
What is the biosimilar risk for Synercid?
Synercid is a small-molecule antibiotic combination, not a biologic. Biosimilar risk is therefore not the relevant framework; instead, generic/combination-product substitution risk applies. This section does not require biosimilar patent logic.
How does Synercid compare with current MRSA and Gram-positive hospital alternatives?
A comparative analysis for hospital antibiotics hinges on:
- target pathogens (MRSA, VRE, streptococci, enterococci susceptibility)
- PK/PD and efficacy in bloodstream infections
- safety and infusion burden
- cost and formulary placement
The provided input does not include Synercid-specific comparative outcomes, but the market reality is that clinicians tend to choose:
- linezolid for MRSA/VRE coverage with oral step-down convenience
- daptomycin for MRSA bacteremia with a well-established safety profile in many settings
- newer MRSA-active beta-lactams when appropriate for MSSA or broad-spectrum de-escalation
Without trial-level comparative evidence in the prompt, only the competitive category mapping can be stated, not a superiority claim.
Clinical trial strategy: what would need to happen for Synercid to regain growth?
A credible growth scenario would require one of the following:
- Label expansion based on a modern randomized trial with active comparators
- A new formulation or administration improvement that changes hospital workflow and reduces adverse events
- Strong niche capture through susceptibility-driven guidelines or combination therapy recommendations
No active or completed trial dataset is provided, so this section frames the only practical commercial pathways without citing specific studies.
Market projection: base-case decline model and upside/downside scenarios (directional)
Because numeric inputs are absent, the forecast can only be structured as scenario logic:
Base case
- Continued incremental use in hospitals for susceptible Gram-positive infections
- Modest year-over-year declines driven by substitution by modern MRSA/VRE regimens and stewardship restriction to reserve cases
Upside case
- Temporary utilization spikes from formulary reversals, supply constraints at competitors, or antibiogram shifts favorable to streptogramins
- New evidence supporting targeted use in specific resistant phenotypes
Downside case
- Sustained formulary exclusion in major hospital systems
- Acceleration of hospital pharmacy switch to linezolid/daptomycin pathways
- Supply chain disruptions or pricing pressure that reduce availability despite demand
Key forecast drivers to monitor
- hospital formulary placement and restriction status
- competitor market share changes (MRSA-focused agents)
- antibiotic stewardship policy changes for Gram-positive resistant infections
- drug supply and pricing for reserve antibiotics
Key Takeaways
- SYNERCID’s commercial profile is niche and hospital-concentrated, with growth constrained by substitution from widely adopted MRSA/VRE-active agents.
- A complete clinical trials update cannot be compiled from the provided input because no trial identifiers or recent milestone data are included.
- Exclusivity, patent barriers, and generic entry risks require Orange Book and litigation data not present in the prompt, preventing accurate timing projections.
- Revenue outlook is best treated as a declining base with scenario-based volatility tied to formulary dynamics and susceptibility-driven demand, not a scale-up growth curve.
FAQs
- What antibiotics most commonly replace Synercid in hospital formularies for MRSA?
- How do hospital stewardship policies influence continued use of streptogramin antibiotics like Synercid?
- What events at competitor manufacturers (supply constraints) can temporarily shift usage toward Synercid?
- What endpoints would support Synercid label expansion in complicated skin and soft tissue infections?
- How would a generic or authorized generic launch change Synercid’s US hospital pricing and volume?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-17).
- FDA Drug Approval Reports and Labeling for SYNERCID. (Accessed 2026-05-17).
- ClinicalTrials.gov. SYNERCID (quinupristin/dalfopristin) search results. (Accessed 2026-05-17).
